Polymer type | NPs preparation method | Loaded materials | Stabilizer | Cell line | Size (nm) | Zeta (mV) | References |
Chitosan | Chemical reaction | - | - | Caco-2 | (418 ± 31)-(531 ± 54) | (13.6 ± 0.8) - (29.4 ± 0.8) | [50] |
Chitosan | Ionotropic gelation | Covalent conjugation with fluorescein- 5-isothiocyanate | - | A549 cells | 195 | 35.5 | [51] |
Chitosan (Galactosylated) | Carbodiimide method | DNA | - | HepG2, HeLa | 100 - 240 | −5 | [52] |
Chitosan {Arg-Gly-Asp (RGD) peptide-labeled} | Ionic gelation | siRNA | - | SKOV3ip1, HeyA8, A2780, A2780ip2, MOECs | 200 | −40 | [53] |
Chitosan, PS, PEG-PLA | Multiple emulsion-solvent evaporation | - | Sodium Cholate | Caco-2, MTX-E12 | (196 ± 20)-(290 ± 7) | (−23.9 ± 1.2) - (1.1 ± 1) | [7] |
Chitosan-PEG | Ionic gelation | Caspase inhibitor pebptide | - | Mice | 150 | 16 | [54] |
Gelatin | Desolvation | Anti CD3 mAb | - | HeLa | 250 - 300 | −20 | [55] |
Heparin | Coupling reaction through amide linkage | Paclitaxel, Folic acid | - | KB-3-1, Tu212 | 60 | −16 | [56] |
Hyaluronic acid (Self-assembled) | Chemical conjugation through Carbodiimide method | - | PBS | SCC7, CV-1 | 237 - 424 | - | [57] |
Hyaluronic acid-ceramide | Self-assembly | Docetaxel | Pluronic P85 | U87-MG, MCF-7, MCF-7/ADR | 110 - 140 | −20 | [58] |
Hydrophobically modified glycol chitosan | Self-assembly | - | - | HeLa | 359 | 22 | [59] |
Mesoporous silica | - | - | - | 3T3-L1, HMSCs | 108 - 115 | (−4.9) - (19) | [60] |
Methyl ether poly(ethylene glycol)-modified poly(beta-amino ester) | Solvent casting | Doxorubicin | - | B16F10 | 62 | - | [61] |
NAcHis-GC (self-assembled) | - | Paclitaxel | PBS | HeLa, A549 | 150 - 250 | - | [62] |
P(MDS-co-CES) | Self-assembly | DNA, Paclitaxel, Indomethacin, Pyrene | - | HEK293, HepG2, MDA-MB-231 | (83 ± 1) - (180 ± 2) | (44 ± 2) - (84 ± 5) | [63] |
PCL | Solvent displacement | Tamoxifen | Pluronic® F-68 | MCF-7 | 250 - 300 | 6 - 25 | [64] [65] |
PCL | Emulsification diffusion | - | - | - | 120 - 125 | (−32) - (−60) | [66] |